Complement Proteins L-Ficolin and M-Ficolin Are Increased in Patients With Axial Spondyloarthritis and Decrease After Tumor Necrosis Factor Inhibitor Treatment.

Autor:	Mistegaard CE; C.E. Mistegaard, MD, Department of Rheumatology, Aarhus University Hospital, Aarhus, Department of Clinical Medicine, Aarhus University, Aarhus, Institute of Regional Health Research, University of Southern Denmark, Odense, and Department of Biomedicine, Aarhus University, Aarhus., Troldborg A; A. Troldborg, MD, PhD, Department of Rheumatology, Aarhus University Hospital, Aarhus, Department of Clinical Medicine, Aarhus University, Aarhus, and Department of Biomedicine, Aarhus University, Aarhus., Hansen A; A. Hansen, BA, Department of Biomedicine, Aarhus University, Aarhus., Thiel S; S. Thiel, PhD, Department of Biomedicine, Aarhus University, Aarhus., Jurik AG; A.G. Jurik, MD, PhD, R.M. Kiil, MD, PhD, Department of Clinical Medicine, Aarhus University, Aarhus, Institute of Regional Health Research, University of Southern Denmark, Odense, and Department of Radiology, Aarhus University Hospital, Aarhus., Kiil RM; A.G. Jurik, MD, PhD, R.M. Kiil, MD, PhD, Department of Clinical Medicine, Aarhus University, Aarhus, Institute of Regional Health Research, University of Southern Denmark, Odense, and Department of Radiology, Aarhus University Hospital, Aarhus., Christiansen AA; A.A. Christiansen, MD, PhD, Institute of Regional Health Research, University of Southern Denmark, Odense, and Danish Hospital for Rheumatic Diseases, Sonderborg., Schiøttz-Christensen B; B. Schiøttz-Christensen, MD, PhD, Research Unit of General Practice, University of Southern Denmark, Odense., Hendricks O; O. Hendricks, MD, PhD, Institute of Regional Health Research, University of Southern Denmark, Odense, and Danish Hospital for Rheumatic Diseases, Sonderborg., Pedersen SJ; S.J. Pedersen, MD, PhD, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Hea.d and Orthopedics, Rigshospitalet Glostrup, Glostrup., Sørensen IJ; I.J. Sørensen, MD, PhD, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet Glostrup, Glostrup., Østergaard M; M. Østergaard, MD, PhD, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet Glostrup, Glostrup, and Department of Clinical Medicine, University of Copenhagen Faculty of Health and Medical Sciences, Copenhagen., Loft AG; A.G. Loft, MD, PhD, Department of Rheumatology, Aarhus University Hospital, Aarhus, Department of Clinical Medicine, Aarhus University, Aarhus, and Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark.
Jazyk:	angličtina
Zdroj:	The Journal of rheumatology [J Rheumatol] 2023 Sep 15. Date of Electronic Publication: 2023 Sep 15.
DOI:	10.3899/jrheum.2023-0164
Abstrakt:	Objective: We have previously reported elevated levels of the complement lectin pathway proteins L-ficolin and H-ficolin in patients with axial spondyloarthritis (axSpA) compared with healthy controls. The aim of the present study was to investigate these biomarkers in a cross-sectional cohort of patients suffering from low back pain (LBP). Further, we aimed to investigate changes in lectin pathway protein levels after initiation of adalimumab (ADA; a tumor necrosis factor inhibitor) in a longitudinal cohort of patients with axSpA. Methods: Lectin pathway protein levels (mannan-binding lectin [MBL], collectin liver 1, H-ficolin, L-ficolin, M-ficolin, MBL-associated serine protease [MASP]-1, MASP-2, MASP-3, MBL-associated protein 19 [MAp19], and MAp44) in EDTA plasma were determined in 2 well-characterized cohorts: (1) a clinical cross-sectional cohort of patients with LBP, including patients with axSpA (n = 23), patients with unspecific LBP (uLBP) with ≥ 1 SpA features (n = 55), and patients with uLBP without SpA features or magnetic resonance imaging findings suggestive of axSpA (n = 64); and (2) a randomized double-blinded, placebo-controlled trial cohort of patients with axSpA (n = 49) initiating ADA therapy. Lectin pathway protein levels were determined using immunoassays. Results: Plasma levels of L-ficolin and M-ficolin were significantly increased in the cross-sectional cohort of newly diagnosed patients with axSpA compared with clinically relevant controls with uLBP (all P < 0.05). Both L-ficolin and M-ficolin decreased significantly after ADA therapy ( P < 0.05). Conclusion: L-ficolin and M-ficolin levels are elevated in newly diagnosed patients with axSpA compared with clinically relevant controls. Both L-ficolin and M-ficolin levels decrease significantly after initiating ADA therapy. These findings provide new insights into the inflammatory processes in axSpA and support the involvement of complement in axSpA pathogenesis.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu